Summary

ALTER0302, a randomized double-blind controlled phase 2 trial, examined the efficacy and safety of anlotinib, a multitargeted tyrosine kinase inhibitor, as third-line therapy for Chinese patients with advanced non–small cell lung cancer. Progression-free survival and objective response rates were increased in all subgroups of patients treated with anlotinib with no associated serious adverse events.